CCXI · Chemocentryx, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Price · CCXI
Income Statement
| Line item | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.76M | $5.46M | - | $17.74M | $1.81M | $10.35M | - | $5.08M | $49.44M | $6.01M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $14.36M | $17.48M | - | $19.95M | $20.85M | $23.42M | - | $18.58M | $18.76M | $19.31M |
| SG&A | $19.70M | $16.26M | - | $19.60M | $19.70M | $16.26M | - | $10.36M | $10.29M | $8.82M |
| Total Operating Expenses | $43.34M | $43.69M | - | $39.55M | $40.55M | $39.68M | - | $28.94M | $29.05M | $28.13M |
| D&A | - | $1.02M | - | - | - | $117.0K | - | - | - | $143.0K |
| Operating Income | ($31.57M) | ($38.23M) | - | ($21.80M) | ($38.74M) | ($29.33M) | - | ($23.86M) | $20.39M | ($22.12M) |
| Interest Expense | $586.0K | $597.0K | - | $668.0K | $695.0K | $689.0K | - | $700.0K | $695.0K | $548.0K |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($31.65M) | ($38.61M) | - | ($22.31M) | ($39.21M) | ($29.71M) | - | ($24.06M) | $20.27M | ($21.69M) |
| EPS - Basic | ($0.44) | - | - | - | ($0.56) | - | - | - | ($0.26) | - |
| EPS - Diluted | - | - | - | - | ($0.56) | - | - | - | $0.29 | - |
Balance Sheet
| Line item | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $44.40M | $40.58M | $49.98M | $93.73M | $77.20M | $68.55M | $32.30M | $56.18M | $333.20M | $59.44M |
| Accounts Receivable | - | - | - | - | - | - | - | $102.0K | $228.0K | $168.0K |
| Inventory | $5.47M | $2.90M | $851.0K | - | - | - | $0 | - | - | - |
| Accounts Payable | $7.59M | $5.42M | $6.75M | $4.41M | $11.09M | $10.93M | $12.88M | $8.87M | $3.41M | $2.37M |
| Current Assets | $345.17M | $351.63M | $269.18M | $293.38M | $317.13M | $390.64M | $441.57M | $474.44M | $507.23M | $186.67M |
| Total Assets | $419.39M | $440.45M | $425.65M | $454.85M | $467.67M | $499.11M | $518.90M | $533.04M | $542.04M | $197.30M |
| Current Liabilities | $76.08M | $68.81M | $63.02M | $60.03M | $55.38M | $54.73M | $51.56M | $46.86M | $56.37M | $57.95M |
| Long-term Debt | $4.00M | $4.55M | $4.71M | $9.56M | $11.57M | $14.87M | $18.10M | $21.26M | $24.25M | $24.18M |
| Total Liabilities | $182.86M | $181.73M | $139.53M | $138.95M | $137.40M | $138.11M | $133.29M | $128.22M | $120.90M | $137.14M |
| Stockholders' Equity | $236.53M | $258.72M | $286.12M | $315.89M | $330.27M | $361.00M | $385.61M | $404.82M | $421.14M | $60.16M |
| Retained Earnings | ($687.36M) | ($655.71M) | ($617.10M) | ($576.57M) | ($554.26M) | ($515.05M) | ($485.34M) | ($455.47M) | ($431.41M) | ($451.67M) |
Cash Flow
| Line item | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | $8.83M | - | - | - | ($21.57M) | - | - | - | ($27.45M) |
| Investing Cash Flow | - | ($21.34M) | - | - | - | $60.67M | - | - | - | $32.03M |
| Financing Cash Flow | - | $3.10M | - | - | - | ($2.85M) | - | - | - | $15.68M |
| CapEx | - | $224.0K | - | - | - | $10.88M | - | - | - | $868.0K |
| Free Cash Flow | - | $8.61M | - | - | - | ($32.45M) | - | - | - | ($28.31M) |
Ratios
| Metric | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -268.4% | -700.4% | - | -122.9% | -2136.7% | -283.3% | - | -469.2% | 41.2% | -368.2% |
| EBITDA margin | - | -681.7% | - | - | - | -282.1% | - | - | - | -365.8% |
| Net margin | -269.1% | -707.2% | - | -125.7% | -2162.7% | -287.0% | - | -473.2% | 41.0% | -361.0% |
| Free cash flow margin | - | 157.7% | - | - | - | -313.4% | - | - | - | -471.3% |
| FCF / Net income | - | -0.22 | - | - | - | 1.09 | - | - | - | 1.31 |
| R&D / Revenue | 122.0% | 320.1% | - | 112.4% | 1150.2% | 226.2% | - | 365.4% | 37.9% | 321.4% |
| SG&A / Revenue | 167.5% | 297.9% | - | 110.5% | 1086.5% | 157.1% | - | 203.8% | 20.8% | 146.8% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -7.5% | -8.8% | - | -4.9% | -8.4% | -6.0% | - | -4.5% | 3.7% | -11.0% |
| Return on equity | -13.4% | -14.9% | - | -7.1% | -11.9% | -8.2% | - | -5.9% | 4.8% | -36.0% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 4.54 | 5.11 | 4.27 | 4.89 | 5.73 | 7.14 | 8.56 | 10.12 | 9.00 | 3.22 |
| Quick ratio | 4.47 | 5.07 | 4.26 | 4.89 | 5.73 | 7.14 | 8.56 | 10.12 | 9.00 | 3.22 |
| Cash ratio | 0.58 | 0.59 | 0.79 | 1.56 | 1.39 | 1.25 | 0.63 | 1.20 | 5.91 | 1.03 |
| Leverage | ||||||||||
| Debt / Equity | 0.02 | 0.02 | 0.02 | 0.03 | 0.04 | 0.04 | 0.05 | 0.05 | 0.06 | 0.40 |
| Debt / Assets | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.03 | 0.03 | 0.04 | 0.04 | 0.12 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -53.9x | -64.0x | - | -32.6x | -55.7x | -42.6x | - | -34.1x | 29.3x | -40.4x |
| Equity multiplier | 1.77 | 1.70 | 1.49 | 1.44 | 1.42 | 1.38 | 1.35 | 1.32 | 1.29 | 3.28 |
| Liabilities / Assets | 0.44 | 0.41 | 0.33 | 0.31 | 0.29 | 0.28 | 0.26 | 0.24 | 0.22 | 0.70 |
| Efficiency | ||||||||||
| Asset turnover | 0.03 | 0.01 | - | 0.04 | 0.00 | 0.02 | - | 0.01 | 0.09 | 0.03 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | 7d | 2d | 10d |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 548.8% | -47.3% | - | 248.9% | -96.3% | 72.3% | - | -51.9% | 589.3% | -27.8% |
| Revenue CAGR (3y) | 17.9% | -13.1% | - | 25.5% | -50.6% | 2.7% | - | -17.4% | 76.9% | -10.0% |
| Revenue CAGR (5y) | 5.6% | -7.9% | - | 33.1% | -8.3% | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 18.5% | -30.4% | - | 8.6% | - | -32.6% | - | -75.0% | - | -76.6% |
| Net income growth (YoY) | 19.3% | -29.9% | - | 7.3% | - | -37.0% | - | -87.1% | - | -81.5% |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | -14.6% | - | - | - | - |
| FCF CAGR (5y) | - | -19.8% | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -28.4% | -28.3% | -25.8% | -22.0% | -21.6% | 500.1% | 484.3% | 554.4% | 489.3% | -25.4% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ChemoCentryx against the 5 most active filers in the same SIC group.